Standard

Assessment of polygenic risk of hypertension. / Limonova, A. S.; Ershova, A. I.; Kiseleva, A. V. и др.

в: Cardiovascular Therapy and Prevention (Russian Federation), Том 21, № 12, 3464, 2022.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Limonova, AS, Ershova, AI, Kiseleva, AV, Ramensky, VE, Vyatkin, YV, Kutsenko, VA, Meshkov, AN & Drapkina, OM 2022, 'Assessment of polygenic risk of hypertension', Cardiovascular Therapy and Prevention (Russian Federation), Том. 21, № 12, 3464. https://doi.org/10.15829/1728-8800-2022-3464

APA

Limonova, A. S., Ershova, A. I., Kiseleva, A. V., Ramensky, V. E., Vyatkin, Y. V., Kutsenko, V. A., Meshkov, A. N., & Drapkina, O. M. (2022). Assessment of polygenic risk of hypertension. Cardiovascular Therapy and Prevention (Russian Federation), 21(12), [3464]. https://doi.org/10.15829/1728-8800-2022-3464

Vancouver

Limonova AS, Ershova AI, Kiseleva AV, Ramensky VE, Vyatkin YV, Kutsenko VA и др. Assessment of polygenic risk of hypertension. Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(12):3464. doi: 10.15829/1728-8800-2022-3464

Author

Limonova, A. S. ; Ershova, A. I. ; Kiseleva, A. V. и др. / Assessment of polygenic risk of hypertension. в: Cardiovascular Therapy and Prevention (Russian Federation). 2022 ; Том 21, № 12.

BibTeX

@article{ee92504529224a80bcb05b0c5aaa3822,
title = "Assessment of polygenic risk of hypertension",
abstract = "Hypertension (HTN) is a leading risk factor for the development of cardiovascular diseases. In recent decades, the rapid development of genetic tests, in particular genome-wide association study (GWAS), has made it possible to identify hundreds of nucleotide sequence variants associated with the development of HTN. One approach to improve the predictive power of genetic testing is to combine information about many nucleotide sequence variants into a single risk assessment system, often referred to as a genetic risk score. Within the framework of this review, the most significant publications on the study of the genetic risk score for HTN will be considered, and the features of their development and application will be discussed.",
keywords = "genetic risk score, hypertension",
author = "Limonova, {A. S.} and Ershova, {A. I.} and Kiseleva, {A. V.} and Ramensky, {V. E.} and Vyatkin, {Yu V.} and Kutsenko, {V. A.} and Meshkov, {A. N.} and Drapkina, {O. M.}",
note = "Публикация для корректировки.",
year = "2022",
doi = "10.15829/1728-8800-2022-3464",
language = "English",
volume = "21",
journal = "Cardiovascular Therapy and Prevention (Russian Federation)",
issn = "1728-8800",
publisher = "Vserossiiskoe Obshchestvo Kardiologov",
number = "12",

}

RIS

TY - JOUR

T1 - Assessment of polygenic risk of hypertension

AU - Limonova, A. S.

AU - Ershova, A. I.

AU - Kiseleva, A. V.

AU - Ramensky, V. E.

AU - Vyatkin, Yu V.

AU - Kutsenko, V. A.

AU - Meshkov, A. N.

AU - Drapkina, O. M.

N1 - Публикация для корректировки.

PY - 2022

Y1 - 2022

N2 - Hypertension (HTN) is a leading risk factor for the development of cardiovascular diseases. In recent decades, the rapid development of genetic tests, in particular genome-wide association study (GWAS), has made it possible to identify hundreds of nucleotide sequence variants associated with the development of HTN. One approach to improve the predictive power of genetic testing is to combine information about many nucleotide sequence variants into a single risk assessment system, often referred to as a genetic risk score. Within the framework of this review, the most significant publications on the study of the genetic risk score for HTN will be considered, and the features of their development and application will be discussed.

AB - Hypertension (HTN) is a leading risk factor for the development of cardiovascular diseases. In recent decades, the rapid development of genetic tests, in particular genome-wide association study (GWAS), has made it possible to identify hundreds of nucleotide sequence variants associated with the development of HTN. One approach to improve the predictive power of genetic testing is to combine information about many nucleotide sequence variants into a single risk assessment system, often referred to as a genetic risk score. Within the framework of this review, the most significant publications on the study of the genetic risk score for HTN will be considered, and the features of their development and application will be discussed.

KW - genetic risk score

KW - hypertension

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85168156270&origin=inward&txGid=426b7a2fac220fc16b32f26f6e9d8f3d

UR - https://www.mendeley.com/catalogue/6f0e5a4c-68a0-3222-8ade-145147683b7b/

U2 - 10.15829/1728-8800-2022-3464

DO - 10.15829/1728-8800-2022-3464

M3 - Article

VL - 21

JO - Cardiovascular Therapy and Prevention (Russian Federation)

JF - Cardiovascular Therapy and Prevention (Russian Federation)

SN - 1728-8800

IS - 12

M1 - 3464

ER -

ID: 55721356